ICON
announced that it has been chosen by
Bristol-Myers Squibb Company
as a preferred provider for full-service clinical pharmacology and exploratory clinical studies. This latest agreement with Bristol-Myers-Squibb follows the company’s selection of ICON to provide global support for Bristol-Myers-Squibb’s clinical development pipeline, which was announced in June 2010.
Under the preferred provider agreement for early phase development, ICON will provide a broad range of clinical pharmacology and exploratory clinical trial services including study conduct in ICON's Clinical Pharmacology Units, located in San Antonio, Texas; Omaha, Nebraska; and Manchester, UK. ICON will also provide all supporting scientific services such as protocol design and development, project management, clinical monitoring, medical monitoring / pharmacovigilence, data management, biostatistics, pharmacokinetics, and medical writing.
“We are pleased that Bristol-Myers-Squibb has again chosen ICON to bring greater operational efficiencies and high quality science to their drug development programs,” commented Dr. Mario Rocci, President, ICON Development Solutions. “Both companies already have a very successful global partnership for phase II-IV clinical development and central laboratory services and we look forward to demonstrating the same value and efficiencies to Bristol-Myers-Squibb’s early phase clinical programs. Our global network of clinical research units, scientists and project teams, underpinned by world class technology, will drive significant cost savings and productivity.”
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.